Bayer Dealt Setback in Alka-Seltzer PPA Case
This article was originally published in The Tan Sheet
Executive Summary
A jury award in favor of a plaintiff who used phenylpropanolamine-containing Alka-Seltzer may not bode well for Bayer in its ongoing PPA litigation
You may also be interested in...
Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany
Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany
Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany